Ingen Technologies, Inc. (Pink Sheets: IGNT) appears to be properly positioned and ready to rapidly scale its business to the likes of other medical device makers, like Thoratec Corporation (Nasdaq: THOR) and Abiomed, Inc. (Nasdaq: ABMD), after securing key government licenses and preparing its products for export. With all barriers now removed, investors look forward to additional contracts and increased revenues.
The emerging medical device manufacturer focused on the respiratory industry has developed unique oxygen cannulas that improve patient comfort and reduce provider support costs. Since Ingens’ cannulas are priced at roughly the same cost as traditional cannulas, yet offer piece of mind for the patient knowing that oxygen is flowing, the company is well-positioned to capture significant market share in the $400-500 million per year oxygen cannula industry.
One of the key barriers to bringing their products to market was the lack of appropriate licensing to conduct government and export sales. But recently, Ingen has acquired both of these licenses and projected that it is on track to realize $1.4 million in initial sales by the end of the year. This makes IGNT a stock that is certainly worth watching for investors looking for growth opportunities.
Ingen Secures Registration for Military Sales
On August 30, 2010, Ingen announced that it received a letter of confirmation from the Armed Services Association in Washington, D.C. stating that it is now registered with the U.S. Central Contractor Registry (CCR), which qualifies it to do business with the U.S. Department of Defense. Inclusion in the U.S. Military Purchasing Directory will put its products in front of potential military customers.
Meanwhile, the company has also been embarking on a number of military conferences designed to drum up interest and showcase its products to prospective buyers. Recently, its partner, KGMA, announced that it successfully demonstrated Ingen’s products at the 13th Annual Force Health Protection Conference in Arizona. Ingen has scheduled additional conferences for later this year.
In May 2010, KGMA also provided a field study showing that approximately 60 facilities would purchase $1.2 million of Ingen’s respiratory products over the next three to four months. KGMA visited these facilities on behalf of Ingen and demonstrated the new Oxyview and Smart Nasal Cannula, while noting that these facilities indicated interest in buying the products.
Ingen Attains ISO Certification to Sell Internationally
In March of 2010, Ingen also obtained certification under the ISO 13485, which enables it to sell internationally. With COPD projected to become the third largest killer in the developed world by 2020, the end markets for oxygen cannulas continues to rapidly expand. As one of the only innovators in the field, Ingen’s cannulas offer a clear value proposition and could capture a significant market share.
The ISO certification opens the door to deliver on existing backorders to countries in Europe and Asia, as well as countries like Canada and Australia.
Conclusions
Ingen has projected that its total 2010 sales will reach $11 million, supported by growth in military, commercial and international market opportunities. With all of its necessary certifications in line, investors can now look forward to the company executing on its plans and delivering value to shareholders.

